共查询到19条相似文献,搜索用时 218 毫秒
1.
2.
非酒精性脂肪肝(NAFLD)已经成为常见的肝病之一.NAFLD被认为与遗传、环境、代谢、应激密切相关.此文将从胰岛素抵抗、脂肪酸代谢、氧化应激等相关基因的多态性对NAFLD发病机制的研究作一综述,为NAFLD发病机制的进一步研究提供方向,并探索有效的防治措施. 相似文献
3.
非酒精性脂肪肝分子发病机制的研究进展 总被引:6,自引:2,他引:6
非酒精性脂肪性肝病(nonalcoholic fatry liverdiseasg,NAFLD)是一种常见肝病,且发病率有逐年增加的趋势.本文概述近年来国内外学者在NAFLD发病机制方面的主要成果和观点,探讨在NAFLD发病中基因的作用,旨在阐明NAFLD发病的分子机制. 相似文献
4.
《胃肠病学和肝病学杂志》2020,(8)
随着生活水平的提高及不良生活习惯的养成,非酒精性脂肪性肝病(non-alcoholic fatty liver disease, NAFLD)的发病率已跃居肝病领域的首位,疾病谱包括NAFLD、非酒精性脂肪性肝炎(non-alcoholic steatohepatitis, NASH)、肝纤维化、肝硬化甚至肝癌。虽然目前有许多关于NAFLD的研究,但其发病机制尚不明确,本文就近年NAFLD发病机制方面的研究作一概述,为NAFLD的治疗和预防指引方向。 相似文献
5.
6.
[据J Hepatol 2011年9月报道]题:慢性间歇性缺氧:呼吸新鲜空气与NAFLD的发病机制(作者Lemoine M等)阻塞性呼吸睡眠暂停(OSA)和非酒精性脂肪性肝病(NAFLD)在肥胖者均较常见,因此,OSA与NAFLD的关系日益引起研究者的关注。最近,法国学者Lemoine等进行了一项有关非酒精性脂肪性肝病(NAFLD)发病机制的研究,评估了 相似文献
7.
池肇春 《世界华人消化杂志》2020,28(9):313-329
随着非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)的深入研究,近几年来发现与心血管疾病(cardiovascular disease,CVD)密切相关.现已证明,NAFLD是CVD发生的重要危险因素,也是年青人动脉硬化、冠心病、高血压发病的重要机制.本文就NAFLD对动脉粥样硬化和CVD的影响、发病机制进行综述,以提高肝病和CVD医师的认识水平,为做好防治提供资源. 相似文献
8.
9.
非酒精性脂肪性肝病(NAFLD)已成为西方发达国家慢性肝病的首要病因,在我国已成为仅次于慢性病毒性肝炎的第二大肝病.但是其发病机制尚不清楚,目前仍然没有有效的治疗方式,有研究指出NAFLD与遗传、环境、精神心理因素有关,而且接触相似危险因素的个体间NAFLD的发病率差异较大,疾病进程亦不尽相同,这一事实提示遗传因素及基因多态性与NAFLD发病及进程有关.全基因组关联研究发现PNPLA3(patatin - like phospholipase domain containing 3)基因多态性与NAFLD的遗传易感性及进展有着密切的联系.本综述主要从PNPLA3的结构特征、PNPLA3基因的生物学特征及PNPLA3基因多态性与NAFLD的相关性几个方面进行探讨,从而有利于NAFLD发病机制的阐明,对NAFLD的预防和治疗提供可能. 相似文献
10.
《世界华人消化杂志》2017,(27)
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)患病率上升,已经成为困扰全球的公共卫生问题.越来越多的研究发现,肠道菌群和NAFLD关系密切.本文综述了肠道菌群与NAFLD发病机制的关系,并为NAFLD的防治提供了新思路. 相似文献
11.
随着人们生活方式和饮食结构的改变,非酒精性脂肪性肝病(NAFLD)发病率逐年上升,严重威胁人类健康。NAFLD疗法一直是基础和临床肝病研究的热门领域。近年来,诸多研究揭示omega-3多不饱和脂肪酸(ω3-PUFA)可促进脂肪酸氧化并改善肠道稳态,从而改善脂代谢和肝脏炎症,因而越来越多的临床研究开始将ω3-PUFA运用于NAFLD的治疗中。然而,ω3-PUFA治疗NAFLD的机制尚不明确,相关临床研究也存在一定局限性。主要介绍了ω3-PUFA在NAFLD中发挥的作用以及相关的临床研究结果,并进一步讨论ω3-PUFA治疗NAFLD尚需解决的问题。 相似文献
12.
13.
14.
15.
16.
17.
18.
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD) 在世界范围内发病率成日益上升趋势,其相关基因研究对完善其致病机制,补充其治疗方案及改善预后至关重要.目前,国内外多项实验证实含patatin 样磷脂酶域3(PNPLA3) 基因突变与NAFLD 密切相关,考虑其与肝脏脂... 相似文献
19.
Konstantinos Tziomalos 《World journal of hepatology》2014,6(10):738-744
Nonalcoholic fatty liver disease(NAFLD) is the most common chronic liver disease in developed countries and is associated not only with increased risk for liver disease-related complications but also with higher cardiovascular morbidity. Accordingly, lipid-lowering agents are frequently considered in these patients to reduce cardiovascular risk. However, there have been concerns regarding the safety of these agents in patients with chronic liver diseases. In the present review, we discuss the safety of lipid-lowering agents in patients with NAFLD as well as their effects on both cardiovascular and liver disease in this population. Accumulating data suggest that statins are safe in patients with NAFLD and that they reduce the increased cardiovascular morbidity of this population. However, it is still unclear whether statins are also useful as a treatment for NAFLD per se, since there are very limited and conflicting data on their effects on liver histology. There is also very scarce evidence regarding the safety and efficacy of other lipid-lowering agents in patients with NAFLD. Randomized controlled studies are needed to evaluate the role of lipid-lowering agents and particularly statins for the prevention of both cardiovascular and liver disease-related complications in this high-risk population. 相似文献